Displaying 49 - 60 of 78
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
5

GSK: Holistic patient care in PBC: moving beyond ALP to QoL - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Displaying 49 - 60 of 78